Our Services
Medical Information
Helpful Resources
Published on: 5/21/2026
Leukotriene modifiers are oral asthma medications that block inflammatory molecules called leukotrienes, which are released by immune cells during an asthma response. By either blocking leukotriene receptors or preventing their production, these drugs reduce airway muscle tightening (bronchoconstriction), mucus overproduction, and swelling — helping keep airways open.
Key considerations include proper dosing, monitoring for mood changes and liver function, and how leukotriene modifiers fit into your broader asthma treatment plan. Because asthma symptoms can overlap with other respiratory conditions, understanding what's actually driving your breathing issues is essential before starting or adjusting any medication. Take a free, instant, online symptom check to clarify your symptoms and confidently plan your next steps with your doctor.
Reviewed for medical accuracy: 07/09/2026
Asthma is a chronic respiratory condition characterized by airway inflammation, bronchoconstriction (tightening of the airway muscles), and excess mucus production. For many people with asthma, standard treatments like inhaled corticosteroids (ICS) and short-acting bronchodilators bring relief. However, some patients need additional options. One such group of medicines is leukotriene modifiers. If you've ever wondered how do leukotriene modifiers work, this deep-dive will explain the immune science behind them, describe their benefits and risks, and help you decide whether to discuss them with your doctor.
Leukotrienes are molecules produced by certain immune cells (mast cells, eosinophils, and basophils) during an inflammatory response. In asthma, they contribute to:
Leukotrienes responsible for these effects are called cysteinyl leukotrienes (LTC4, LTD4, LTE4). By targeting these molecules, leukotriene modifiers interrupt key steps in the asthma cascade.
There are two main ways to disrupt leukotriene activity:
By either preventing leukotriene synthesis or blocking their action at the receptor, these drugs reduce airway narrowing, inflammation, and mucus build-up.
Leukotriene modifiers offer several advantages:
| Drug | Typical Dose (Adults) | Frequency | Notes |
|---|---|---|---|
| Montelukast | 10 mg | Once daily | At bedtime |
| Zafirlukast | 20 mg | Twice daily | 1 hour before or 2 hours after meals |
| Zileuton | 600 mg | Four times daily | Monitor liver enzymes |
Children's doses vary by age. Always follow your doctor's prescription and the medication leaflet.
Although generally well tolerated, leukotriene modifiers do carry possible risks:
Common side effects (occur in 1–10% of users):
Less common but important considerations:
Discuss any side effects or mood changes with your healthcare provider. In many cases, benefits outweigh risks when asthma remains uncontrolled by other means.
If your asthma remains uncontrolled, or if you experience severe breathlessness, seek medical attention promptly.
If you're experiencing persistent coughing, wheezing, or shortness of breath and want to understand what might be causing your symptoms, try this free AI-powered symptom checker to get personalized health insights in just 3 minutes and prepare for a more informed conversation with your doctor.
Asthma can be a lifelong condition, but with the right combination of therapies—possibly including leukotriene modifiers—you can achieve good control and maintain an active life. Always discuss significant or worsening symptoms with your doctor. If you experience severe shortness of breath, chest pain, or any life-threatening signs, seek emergency medical care immediately.
Remember: This information is a guide, not a substitute for professional advice. Speak to a doctor about any symptoms that concern you or before making changes to your asthma treatment plan.
(References)
* Singh RK, Kumar S, Prasad DN. Leukotriene pathway in asthma and allergic rhinitis. Indian J Pharmacol. 2020 Nov-Dec;52(6):442-449.
* Montuschi P, Ciucci F, Sestini P. Inflammation in Allergic Airway Diseases: Role of Leukotrienes. Metabolites. 2021 Mar 4;11(3):146.
* Lammers JW. Cysteinyl Leukotriene Receptor 1 Antagonists: A Review of their Role in the Management of Asthma. Clin Rev Allergy Immunol. 2018 Dec;55(3):364-372.
* Riccio MM, Henderson WR Jr, Peters-Golden M. The role of cysteinyl leukotrienes in airway hyperresponsiveness and remodeling. Curr Opin Pulm Med. 2017 Jan;23(1):79-84.
* Molfino NA, Montuschi P. Leukotrienes in airway inflammation: from mechanisms to therapeutic implications. Pulm Pharmacol Ther. 2016 Apr;37:67-75.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.